MDPI and ACS Style
Matsuki, T.; Okamoto, I.; Fushimi, C.; Takahashi, H.; Okada, T.; Kondo, T.; Sato, H.; Ito, T.; Tokashiki, K.; Tsukahara, K.;
et al. Real-World, Long-Term Outcomes of Nivolumab Therapy for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck and Impact of the Magnitude of Best Overall Response: A Retrospective Multicenter Study of 88 Patients. Cancers 2020, 12, 3427.
https://doi.org/10.3390/cancers12113427
AMA Style
Matsuki T, Okamoto I, Fushimi C, Takahashi H, Okada T, Kondo T, Sato H, Ito T, Tokashiki K, Tsukahara K,
et al. Real-World, Long-Term Outcomes of Nivolumab Therapy for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck and Impact of the Magnitude of Best Overall Response: A Retrospective Multicenter Study of 88 Patients. Cancers. 2020; 12(11):3427.
https://doi.org/10.3390/cancers12113427
Chicago/Turabian Style
Matsuki, Takashi, Isaku Okamoto, Chihiro Fushimi, Hideaki Takahashi, Takuro Okada, Takahito Kondo, Hiroki Sato, Tatsuya Ito, Kunihiko Tokashiki, Kiyoaki Tsukahara,
and et al. 2020. "Real-World, Long-Term Outcomes of Nivolumab Therapy for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck and Impact of the Magnitude of Best Overall Response: A Retrospective Multicenter Study of 88 Patients" Cancers 12, no. 11: 3427.
https://doi.org/10.3390/cancers12113427